Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Safety Study of CRB-4001 for the Treatment of Nonalcoholic Steatohepatitis (NASH)

Next Previous
Trial Profile

A Phase I Safety Study of CRB-4001 for the Treatment of Nonalcoholic Steatohepatitis (NASH)

Planning
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2018

At a glance

  • Drugs CRB-4001 (Primary)
  • Indications Fibrosis; Idiopathic pulmonary fibrosis; Interstitial nephritis; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors Corbus Pharmaceuticals

    • Most Recent Events

    • 27 Sep 2018 New trial record
    • 20 Sep 2018 According to a Corbus Therapeutics media release, this trial is expected to begin in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top